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Abstract
Introduction To generate biomarkers of target engagement or predictive response for multi-target drugs is challenging. One 
such compound is the multi-AGC kinase inhibitor AT13148. Metabolic signatures of selective signal transduction inhibi-
tors identified in preclinical models have previously been confirmed in early clinical studies. This study explores whether 
metabolic signatures could be used as biomarkers for the multi-AGC kinase inhibitor AT13148.
Objectives To identify metabolomic changes of biomarkers of multi-AGC kinase inhibitor AT13148 in cells, xenograft / 
mouse models and in patients in a Phase I clinical study.
Methods HILIC LC–MS/MS methods and Biocrates AbsoluteIDQ™ p180 kit were used for targeted metabolomics; fol-
lowed by multivariate data analysis in SIMCA and statistical analysis in Graphpad. Metaboanalyst and String were used for 
network analysis.
Results BT474 and PC3 cells treated with AT13148 affected metabolites which are in a gene protein metabolite network 
associated with Nitric oxide synthases (NOS). In mice bearing the human tumour xenografts BT474 and PC3, AT13148 
treatment did not produce a common robust tumour specific metabolite change. However, AT13148 treatment of non-tumour 
bearing mice revealed 45 metabolites that were different from non-treated mice. These changes were also observed in patients 
at doses where biomarker modulation was observed. Further network analysis of these metabolites indicated enrichment 
for genes associated with the NOS pathway. The impact of AT13148 on the metabolite changes and the involvement of 
NOS-AT13148- Asymmetric dimethylarginine (ADMA) interaction were consistent with hypotension observed in patients 
in higher dose cohorts (160-300 mg).
Conclusion AT13148 affects metabolites associated with NOS in cells, mice and patients which is consistent with the clini-
cal dose-limiting hypotension.
Keywords AT13148 · Targeted metabolomics · NOS · Hypotension · ADMA
1 Introduction
The study of small molecule metabolites utilizing metabo-
lomics is a flourishing technique in the biological milieu. It 
provides insight into normal physiology and pathomecha-
nisms, and tools to characterise phenotypes. In the context 
of drug discovery and development, metabolites provide 
accessible biomarkers (Ang et  al. 2017, 2016; Griffiths 
et al. 2010).This is particularly important where the avail-
ability of human tumour biopsies is limited and the use of 
surrogate tissues, e.g. plasma, is essential to assess target 
engagement. Metabolite changes can be evaluated in mod-
els of increasing complexity, i.e. tumour cells, mouse xen-
ograft studies and clinical samples. In addition to tumour 
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mediated effects, assessment of the compound non-tumour 
related effects has the potential to (i) identify biomarkers, (ii) 
gain better understanding of the mechanism of action and 
(iii) predict potential side effects earlier in the drug devel-
opment process before the clinical phases. We have previ-
ously demonstrated that metabolomic signatures established 
in preclinical studies can be used clinically as biomarkers 
of target engagement and/or predictors of tumour and com-
pound specific responses (Ang et al. 2017, 2016). In these 
studies, a workflow to generate tumour specific and target 
related metabolomic signatures was successfully applied. 
Initially, metabolomic changes in plasma induced by dif-
ferent pathway inhibitors in preclinical studies from tumour 
and in non-tumour bearing mice were measured. These pre-
clinical data sets were used to generate target and tumour 
specific metabolomic signatures which were assessed later 
with plasma samples from patients in a Phase I clinical trial 
(Ang et al. 2017, 2016; Sarker et al. 2015; Yang et al. 2019).
AT13148 is an orally available, potent broad spectrum 
AGC kinase inhibitor. It is an ATP competitive inhibitor 
of PKA (3 nM), ROCK1 (6 nM), ROCK2 (4 nM), p70S6K 
(8 nM), PRK1 (16 nM), AKT1 (38 nM), AKT3 (50 nM), 
SGK3 (63 nM) and RSK1 (85 nM) (Yap et al. 2012). In 
cancer cells, AT13148 blocks phosphorylation of AKT, 
p70S6K, PKA, ROCK, and SGK substrates and induces 
apoptosis; it shows in vivo anti-tumour efficacy in HER2-
positive, PIK3CA-mutant BT474 breast, PTEN-deficient 
PC3 human prostate cancer, and PTEN-deficient MES-SA 
uterine human xenografts in mice (Yap et al. 2012). A dose 
escalation Phase I clinical trial of AT13148 was undertaken 
in patients with advanced solid tumours.
In this study, we tested the effect of AT13148 on cellu-
lar metabolites, plasma metabolites in mice bearing human 
tumour xenografts sensitive to AT13148 and in non-tumour 
bearing mice post treatment. Finally, we compared these pre-
clinical results to metabolite changes observed in the Phase 
1 dose escalation study carried out at the Royal Marsden 
Hospital.
2  Materials and methods
2.1  Cellular screen
BT474 (ATCC lot #3,272,826, 13/02/03) and PC3 (ATCC 
lot #61,573,377 07/07/2015), were profiled and authenti-
cated in house. Cell lines were analyzed by short tandem 
repeat (STR) profiling. Polymorphic STR loci were ampli-
fied using a PCR primer set. The PCR product (each locus 
was labelled with a different fluorophore) was analysed 
simultaneously with size standards by using an automated 
fluorescent detection technique. The number of repeats 
at 7–10 different loci defines the STR profile and was 
cross-referenced with online databases to confirm authen-
ticity. All cell lines showed 100% match and were negative 
for mycoplasma.
BT474 cells were maintained in Dulbecco’s Modified 
Eagle Medium (DMEM)/F-12 supplemented with 10% fetal 
bovine serum and insulin 10 µg/mL. PC3 cells were cultured 
in Dulbecco’s Modified Eagle Medium (DMEM) supple-
mented with 10% fetal bovine serum. Both cell lines were 
kept at 37 °C, 5% CO2 in a humidified incubator and media 
were changed in every 2–3 days and cells were allowed to 
reach 80% confluency before passages.
The cells were incubated with 1 µM AT13148 (to mimic 
in vivo exposure) and the same volume of vehicle control 
(DMSO < 0.1% (v/v).) for 24 h in T25 flasks. Metabolites 
were extracted with methanol at − 80 °C and samples were 
dried under nitrogen to evaporate methanol before LC–MS/
MS analysis.
The selected metabolites and associated proteins were 
analysed to map their interactions in different pathways and 
networks (https ://www.metab oanal yst.ca and https ://strin 
g-db.org/).
2.2  Measurement of cellular ADMA
The effect of AT13148 on the intracellular level of Asym-
metric dimethylarginine (ADMA) was monitored in BT474 
cells treated with AT13148 (1 µM, for 6 and 24 h compared 
with their DMSO controls from the same experiment; 3 
flasks/condition, DMSO < 0.1% (v/v)). The samples were 
analysed with a short HILIC LC–MS/MS method, which 
includes ADMA, (adapted from a method by Shina et al. 
2011).
2.3  Measurement of nitric oxide activity
NOS activity was measured following treatment of BT474 
cells with AT13148 (1 µM, 6 and 24 h; 3 flasks/condition; 
DMSO < 0.1% (v/v)); the cells were washed with PBS 
and analysed for NOS activity by a colorimetric method 
on a Biotech Synergy HT plate reader according to the 
manufacturer`s instructions (Abcam, Cambridge, UK).
2.4  Preclinical mouse studies
BT474 (ATCC lot #3,272,826, 13/02/03) and PC3 (ATCC 
lot #61,573,377 07/07/2015) were profiled and authenticated 
in house (2015) as described above.
For pharmacodynamics and metabolomics experiments 
2 million cells were injected in PBS subcutaneously bilater-
ally into the flanks of female NCr athymic mice 6–8 weeks 
of age, bred in-house. During the experiment, food pellets 
(Certified Rodent Diet 5002, Labdiet, Indianapolis, Indiana, 
USA) and water were available ad libitum. Dosing of the 
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animals was undertaken synchronously under sterile con-
ditions in the same experiment when tumours were well-
established and approximately 8–10 mm in diameter. A 
single dose of 40 mg/kg AT13148 was administered p.o. in 
10% DMSO, 1% TWEEN 20, 89% saline. Control animals 
received an equivalent volume of vehicle.
To observe non-tumour specific metabolic changes, 
non-tumour bearing mice were treated the same way as the 
tumour-bearing mice.
Blood samples were collected at 2, 6 and 24 h after drug 
administration. 3–4 mice were used for each time point per 
treatment.
The blood samples were centrifuged at 13,000 rpm for 
2 min and the plasma transferred onto dry ice; the entire 
process from collection to storage in dry ice took less than 
5 min per sample. Plasma samples were stored at -80 °C 
until further LC–MS/MS analysis.
2.5  Phase I clinical trial of AT13148
Plasma samples for metabolomic analysis were obtained 
from 25 patients with advanced tumours across 5 cohorts as 
part of a dose escalation Phase I study with AT13148 (Clini-
cal trial information: NCT01585701. Demographic profile of 
the trial is summarized in Supplementary Table 1). AT13148 
was administered according to a weekly schedule once per 
day on days 1, 3 and 5. One treatment cycle was 28 days. 
Following a pre-dose sample for baseline levels, Cycle 1 
(Day 7 to 4) blood samples (2 mL) were taken. Blood (with 
sodium heparin as anticoagulant) was centrifuged (1500 g 
for 15 min at 4 °C); the plasma was separated then stored 
at –80 °C until further LC–MS/MS analysis. Metabolomics 
analysis was carried out on samples from patients dosed with 
40 mg, 80 mg, 160 mg, 240 mg or 300 mg of AT13148 daily 
and samples were collected pre-dose, 6, 12 and 24 h post-
dose in Cycle 1.
2.6  Analysis of Clinical PD Biomarkers
GSK3β assay was performed on platelet rich plasma (Banerji 
et al. 2018) using assays validated to Good Clinical Prac-
tice standards on the MesoScale Discovery (MSD®). To 
monitor the phosphorylation status of GSK3β the samples 
were added to the plate followed by a solution containing 
the MSD SULFO-TAGTM labelled detection antibody for 
GSK3β.The plate was then analysed on the MSD SEC-
TORTM Imager 6000 (Yap et al. 2014). The levels of pSer9 
GSK3β, represented as a percent of the pre-treatment levels, 
were normalised to the levels of total GSK3β.
Myosin regulatory light chain 2 (MLC-2) levels of 
phosphorylated Ser19 and total MLC-2 were measured in 
lysates of platelets, isolated from blood by centrifugation, 
by Western blotting using fluorescent tagged IgG secondary 
antibodies and GAPDH as a loading control. The assay was 
validated by the ICR Clinical PD Biomarker group for use 
in clinical trials including low, medium and high Quality 
Controls. Fluorescent detection by LI-COR Odyssey Fc sys-
tem and densitometric analysis of the images was performed 
using Image Studio (LI-COR).
2.7  LC–MS/MS Targeted metabolomics analysis 
of cell and plasma samples
Cells: PC3 and BT474 cell extracts were analysed using 
targeted non-quantitative LC–MS/MS with HILIC chroma-
tography and a positive/negative ion–switching method MS 
(adapted method of Yuan et al. 2012, all monitored metabo-
lites are listed in Supplementary material). Briefly, previ-
ously dried extracts were reconstituted in acetonitrile–water 
(1:1) and analysed by LC–MS/MS on a QTrap6500 mass 
spectrometer (AB Sciex, Warrington, UK). Chromatography 
was performed using a Shimadzu Nexera UPLC system on 
an Amide XBridge HPLC column (3.5 μm; 4.6 mm inner 
diameter (i.d.) × 100 mm length). A gradient mobile phase 
with acetonitrile and 20 mM ammonium acetate, buffered 
at pH 9, was used with flow rate of 0.3 mL/min and a run 
time of 23 min (Yuan et al. 2012). A second shorter HILIC 
method (10 min) for optimisation of arginines (including 
ADMA) was carried out on a similar column and conditions 
using a gradient mobile phase containing 0.5% acetic acid 
with 0.025% TFA (Shina et al. 2011). Analyst® software 
was used for data acquisition.
Plasma: mouse and patient plasma samples were analysed 
using targeted, quantitative metabolomic analysis by electro-
spray ionization tandem MS using the AbsoluteIDQ™ p180 
kit (Biocrates Life Sciences AG, Innsbruck, Austria). Sam-
ples were derivatised using phenylisothiocyanate (PITC). 
Metabolites were extracted and analysed according to the 
manufacturer`s instructions. Preclinical and clinical plasma 
samples were anonymized and randomized and analyses 
were carried out on a Waters Acquity H-class UPLC coupled 
to a Xevo TQ-S triple-quadrupole MS/MS System (Waters 
Corporation, Manchester, UK). Quantification of the metab-
olites of each biological sample was achieved by reference 
to appropriate stable isotope internal standards. The method 
follows the United States Food and Drug Administration 
Guidelines ‘Guidance for Industry—Bioanalytical Method 
Validation (May 2001)’, providing proof of reproducibility 
within a given error range.
2.8  Data analysis
MultiQuant® (version 3.0.3) was used for processing cel-
lular metabolites to monitor their changes compared to con-
trols (after normalization by the total sum of monitored ana-
lyte area). To derive metabolite concentrations in mouse and 
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human plasma the analytical process was performed using 
MassLynx™ and TargetLynx™ (Waters corporation Man-
chester UK) and the MetIDQ™ software package (Biocrates 
Life Sciences, Innsbruck, Austria.)
Multivariate analysis was performed on cellular and 
plasma samples by SIMCA v.15 software (MKS Umetrics 
AB, Sweden); to determine metabolite features that were 
differentially expressed between defined sample groups. 
Metabolites responsible for differences were identified using 
OPLS-DA with a threshold of variable importance in the 
projection (VIP) value ≥ 1 and minimum 0.5  pcorr absolute 
value on S-plot.
For the relevant cell or plasma metabolites the changes 
relative to control concentration (solvent, vehicle or sub-
therapeutic dose) were used to generate heat maps. We tested 
the metabolomics signature identified in non-tumour bearing 
mice in samples from Phase I clinical trial patients.
In clinical plasma samples, changes relative to pre-treat-
ment baseline levels were calculated for each patient across 
all time points for each metabolite and normalised to the 
sub-therapeutic dose, 40 mg, to eliminate the food and time 
of day effects.
The statistical significance of the differences were deter-
mined using Mann–Whitney (cell data) or Kruskall-Wallis 
followed by Dunn`s multiple comparison post hoc (clinical 
data) tests (Graphpad Prism v7 and v8, California, USA), 
and values < 0.05 were considered statistically significant.
The network diagrams were constructed using Meta-
boAnalyst 3.0 (gene-metabolites) and String (proteins) 
(https ://www.metab oanal yst.ca and https ://strin g-db.org/ 
retrospectively).
3  Results and discussion
3.1  Cell experiments
Following treatment of the human breast carcinoma cells 
BT474 and the PC3 prostate carcinoma cells with 1 µM 
AT13148, 20 metabolites were selected based on the fol-
lowing criteria: VIP > 1 and abs  pcorr > 0.5. The average per-
centage changes relative to control are presented in Fig. 1a. 
These included Kynurenic acid, Uridine, 5-oxo-l-proline, 
N-Acetyl-glucosamine 1-phosphate, Citrulline, Citrate, 
Flavin adenine dinucleotide, Nicotinamide, N2-Acetylorni-
thine, Glycerol 3-phosphocholine, L-Tryptophan, Uridine 
5-diphosphate, Creatinine, Malate, Pyridoxine, L-Arginine, 
L-Lysine, Lactate, Xanthine and Urate. Importing these 
metabolites into Metaboanalyst, (Fig. 1b), shows that these 
metabolites are associated with NOS. We therefore decided 
to assess NOS activity in BT474 cells treated with AT13148, 
and measure ADMA, which is a naturally occurring endog-
enous inhibitor of nitric oxide synthases (Latika Sibal et al. 
2010). We found that AT13148 decreases Asymmetric 
dimethylarginine (ADMA) levels and increases NOS activ-
ity compared with controls (Combined 6 and 24 values are 
on Fig. 1c).
3.2  Preclinical and clinical plasma samples
3.2.1  Preclinical tumour specific signature
The effect of AT13148 on mouse plasma metabolites from 
PKPD experiments in the sensitive tumour xenograft models 
BT474 and PC3 was assessed. We sought to identify metab-
olites that were different in tumour bearing mice compared 
with controls and where treatment with AT13148 40 mg/kg 
reversed the effect. After evaluation of the selected metabo-
lite changes, we were not able to generate a robust AT13148 
metabolomics signature (based on the OPLS-DA selection 
criteria) that was reversible and specifically associated with 
tumour-bearing mice that responded to AT13148 (Yap et al. 
2012) and not present in non-tumour bearing animals. This 
could be due to the limited number of sensitive tumours used 
for this analysis and to the fact that AT13148 has multiple 
targets.
3.2.2  Preclinical non‑tumour specific signature
In parallel, with the aim to utilize the non-tumour bearing 
mouse model as a potential tool to predict non-tumour spe-
cific effects of single dose AT13148, we analysed the pre-
clinical plasma samples derived from non-tumour bearing 
mice. We compared metabolite changes in plasma from mice 
treated with 40 mg/kg of AT13148 and their vehicle control 
group. In OPLS-DA analysis, we identified 45 metabolites 
with a minimum VIP value of 1 and minimum absolute value 
of  pcorr 0.5 on S-Plot (Fig. 2a; list of metabolites including 
VIP and  pcorr scores are listed in the supplementary data). 
These include amino acids, biogenic amines, acylcarnitines 
and glycerophospholipids. 36 out of 45 metabolites were 
available in the HMDB database for further network analysis 
(Supplementary figure S1b).
3.2.3  Clinical translation of the signature based 
on preclinical non‑tumour bearing mouse models
Following normalisation to the 40 mg dose to remove the 
time of day variation in plasma metabolites, 44 out of the 45 
metabolites identified in mice following AT13148 treatment 
were also affected in patients. Of note is that these effects 
were only observed at doses of 160 mg and above (Fig. 2a 
and b). The observation that these metabolic effects occurred 
at doses where the biomarkers are modulated confirms that 
they are associated with AT13148.
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The preclinical signature shows the highest correlation 
with the clinical signature from patients at 300 mg where 
on-target biomarker modulation was also observed (Fig. 2 
and Supplementary figure S2). ROCK and AKT associ-
ated inhibition was also confirmed by biomarker changes 
(MLC2 Supplementary figure S3 and GSK3β Figure S4) 
in the clinical trial at doses of 160, 240 and 300 mg. We 
analysed the clinical data set further to investigate statis-
tically significant metabolite dose responses compared 
to the sub-therapeutic 40 mg-samples. Despite the small 
size of the clinical study, we identified the following 10 
metabolites (~ 20% of all metabolites measured) Butenyl-
carnitine (C4:1), Dodecenoylcarnitine (C12:1), L-Lysine 
(Lys), L-Threonine (Thr), Sarcosine, lysoPhosphatidylcho-
line acyl C18:2 (lysoPC a C18:2), lysoPhosphatidylcholine 
acyl C26:1 (lysoPC a C26:1), lysoPhosphatidylcholine acyl 
C28:1 (lysoPC a C28:1), Phosphatidylcholine diacyl C36:0 
(PC aa C36:0), Phosphatidylcholine acyl-alkyl C34:3 (PC ae 
C34:3) from the preclinical signature which showed statisti-
cally significant dose response effects compared with their 
sub-therapeutic levels. Table 1 shows the results of the sta-
tistical analysis and the 10 significantly changed metabolites 
when applying the preclinical signature to clinical samples. 
Figure 3 shows representative examples of the dose depend-
ent effects of AT13148 on selected metabolites (combined 
values of 6–12-24 h).
Further statistical analysis of all detectable clinical 
metabolites and their dose responses in the 5 clinical cohorts 
showed 33 metabolites significantly affected by AT13148 
(Supplementary data).
Table 1  Mean percentage changes compared to predose level (6–12-24 h)
Kruskal–Wallis and Dunn`s test per doses (6–12-24 h); (Ac-Orn excluded, due to BLQ). The 10 statistically significant (Kruskal–Wallis test, 
greyed) metabolites in samples from patients dosed with 80,160,240 and 300 mg and compared to sub-therapeutic 40 mg
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One of the most robust changes was the decreased level 
of Asymmetric dimethylarginine (ADMA) (Kruskal–Wal-
lis p = 0.0044; Supplementary figure S4) (Tran et al. 2003). 
Application of the network explorer option in Metaboanalyst 
on the identified 33 significant metabolites showed that NOS 
enzymes were captured in the constructed network (Sup-
plementary figure S1c).
Finally, we assessed the common genes from the gene-
metabolites networks derived from cells, the preclinical sig-
nature and the clinical signature. Genes with a minimum of 
2 degree interaction were selected. Twelve common genes 
(Fig. 4a) were identified in all three networks. Based on 
this information we generated a protein network in String; 
7 out of 12 proteins showed direct interaction; they were 
also linked to nitric oxide synthase (NOS2) (Fig. 4b). NOS 
enzymes are controlled by multiple co- and post-transla-
tional lipid modifications via endomembrane specific regu-
lation by several classes of signalling molecules, including 
phosphatidylinositol 3,4,5-trisphosphate (Sato et al. 2003), 
Ras (Bivona and Philips 2003), and G proteins (Stow and 
Heimann 1998). Endothelial NOS (NOS3) activity is also 
regulated by phosphorylation and by protein–protein inter-
actions (Fulton et al. 2004). ROCK negatively regulates the 
function of endothelial nitric oxide synthase eNOS (NOS3) 
by inhibiting AKT phosphorylation of eNOS on Ser-1177 
leading to decreased NO production (Ming et al. 2002). Inhi-
bition of AKT was observed in our clinical study with a 
concentration dependent inhibition of the ratio of phospho-
rylated over total GSK3β (Fig. 4c). The impact of AT13148 
on the metabolite changes, including a significant and 
Fig. 1  Summary of in  vitro cellular work a Average changes of 
selected 20 metabolites of BT474 and PC3 cells, b Metabolite- Gene 
network based on 20 selected metabolites modulated by AT13148 
in cells (including NOS1, NOS2, NOS3). c Averages of 6 and 24 h 
changes (± SEM) of intracellular level of Asymmetric dimethylar-
ginine (ADMA) decreased in the presence of AT13148 and induced 
NOS activity in BT474 cells
Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients…
1 3
Page 7 of 11    50 
dose-dependent decrease of Asymmetric dimethylarginine 
(ADMA) and the involvement of NOS, was associated with 
hypotension observed in patients at the higher doses of 160, 
240 and 300 mg (Fig. 4c). The direct interaction between 
ADMA-NOS and AT13148 is consistent with our measure-
ments of NOS activity and Asymmetric dimethylarginine 
levels in BT474 cells, (Fig. 1c) and the vascular smooth 
muscle contraction, hypotension, and tachycardia seen in 
mice treated with AT13148 (Yap et al. 2012). Asymmetric 
dimethylarginine (ADMA) is a naturally occurring endog-
enous inhibitor of nitric oxide synthases (Latika Sibal et al. 
2010, Tran et al. 2003). The decreased level of ADMA may 
have been caused by inhibition of protein arginine meth-
yltransferase type 1 (PRMT1) which is responsible for 
the formation of NG-monomethyl-L-arginine (LNMMA) 
and NG, NG-dimethyl-L-arginine (ADMA) (Latika Sibal 
et al. 2010, Tran et al. 2003). In addition, dimethylarginine, 
dimethylaminohydrolases (DDAHs), enzymes removing 
methylarginines, such as ADMA, could have some influence 
on the AT13148 associated metabolic changes/pathways 
observed; DDAH1 is involved in Ras-pathway regulation 
therefore indirectly could have an impact on NOS activity, 
while DDAH2 binds directly to PKA which can also be asso-
ciated with the increased lipid changes observed in plasma 
samples (Leiper and Vallance 2006). Our results suggest that 
the underlying mechanism of the clinically observed hypo-
tension (in systolic arterial pressure in the supine position) 
triggered by AT13148 might be an increased ADMA-sensi-
tive NOS activation resulting in elevated production of the 
endogenous vasodilator NO. It is consistent with previous 
observations with the ROCK inhibitor fasudil which is used 
in Japan for cerebral vasospasm (Murakami et al. 2019).
We observed significant increases in lipids both in non-
tumour bearing mice and in patients. AT13148 inhibits AKT 
Fig. 2  Heatmaps illustrating the changes of a the preclinically selected metabolites in (non-tumour bearing) mice and b preclinical signature 
translated to the clinic
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which has been shown to enhance de novo lipid synthesis 
in the liver (Yecies et al. 2011). In patients, reduction of 
GSK3β phosphorylation was observed indicating inhibition 
of AKT. Although we have not demonstrated a clear inhibi-
tion of PKA, AT13148 is also a potent PKA inhibitor. PKA 
phosphorylates numerous enzymes in lipid signalling includ-
ing, for example, acetyl CoA carboxylase, which inhibits 
lipid synthesis and inactivates phospholipase C. This may 
explain the observed dose dependent increase of glycer-
ophospholipids (lysoPhosphatidylcholines (lysopPCs) and 
Phosphatidylcholines(PCs) (Sassone-Corsi 2012; Liao et al. 
2007; Ming et al. 2002; Pearce et al. 2010).
4  Conclusions
This is our third study successfully utilizing targeted 
LC–MS/MS metabolomics to identify compound related 
changes in preclinical and clinical samples. Previously, in 
two selective signal transduction inhibitor (PI3K and MEK) 
studies, we have demonstrated that targeted LC–MS/MS 
metabolomics is a powerful approach in cancer biomarker 
studies and has the capability to establish metabolomic sig-
natures of target engagement and predictive response. Based 
on preclinical xenograft models, tumour specific metabolite 
changes were identified upon treatment with inhibitors and 
successfully applied to the clinic. AT13148 is a pan AGC-
kinase inhibitor and we were unable to establish a tumour 
specific signature as the metabolic effects observed in sensi-
tive tumour cells are also seen in normal tissues. Although 
this is a Phase I study with a limited number of patients 
with heterogenous cancers treated at different dose levels, 
many of the metabolites modulated by AT13148 in patients’ 
plasma were also affected in mice. Despite the fact that the 
Fig. 3  Representative examples of statistically significant metabolite 
changes in patient samples across clinical cohorts. Sarcosine, Bute-
nylcarnitine (C4:1), L-Threonine(Thr), lysoPhosphatidylcholine acyl 
C18:2(lysoPC a C18:2), Phosphatidylcholine acyl-alkyl C34:3 (PC 
ae C34:3) Mean (± SEM) of percentage changes compared to predose 
level, KW: Kruskal–Wallis, D: Dunn’s test
◂
Fig. 4  Summary of NOS, ADMA, AKT and hypotension associated 
results and observations. a Venn diagram of genes selected from 
cells, preclinical and clinical networks b Protein network of the com-
mon genes in String includes: Nitric oxide synthase (NOS2), Orni-
thine decarboxylase (ODC1), Catalase (CAT), Alpha-S1-casein 
(CSN1S1), Arginase-1 (ARG1), Arginase-2 (ARG2), Serum albu-
min (ALB). c Clinically observed, mean (± SEM), dose dependent 
decrease of Asymmetric dimethylarginine (ADMA) (6 h) and pSer19: 
Total GSK3β (6 h) resulting in increasing level of hypotension(4 h) 
(differences increased in systolic arterial pressure in supine position)
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gene-metabolite-protein combined network analysis relies on 
pre-existing data bases with their own limitations, cellular, 
animal data and patient analysis consistently associated the 
metabolic signature with the NOS pathway. This was further 
validated with ADMA and NOS measurement.
Our data suggest that AT13148 activates NOS resulting in 
elevated production of the natural vasodilator NO resulting 
in the clinical dose-dependent hypotension observed.
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